Bone problems: latest news

Bone problems resources

  • Longer-term side-effects

    Effective HIV treatment has significantly reduced the risk of serious kidney disease in people with HIV. However, most anti-HIV drugs can cause some damage to the kidneys, so...

    From: Booklets

    Information level Level 2
  • Other tests

    Blood pressure is the force that the beating heart causes in the arteries, veins, and blood vessels that carry blood around the body. Blood pressure is measured...

    From: Booklets

    Information level Level 2
  • Side effects

    The most common side effects are the result of your body getting used to a new drug. After a few weeks, these side effects usually...

    From: The basics

    Information level Level 1
  • HIV treatment, metabolic changes and ageing

    Anti-HIV drugs can cause changes inside your body, known as metabolic changes. These can include: changes to blood fats (also called lipids), such as having too much low-density (LDL, or...

    From: Booklets

    Information level Level 2
  • Bone loss

    Osteoporosis has traditionally been a disease affecting women past the age of menopause. However, studies have established that osteoporosis is also common amongst HIV-positive men...

    From: HIV treatments directory

    Information level Level 4
  • Osteonecrosis

    Osteonecrosis, literally 'bone death', is caused by poor blood supply to an area of bone. Like the other bone disorder osteoporosis, osteonecrosis has only recently...

    From: HIV treatments directory

    Information level Level 4
  • Osteoporosis and osteopenia

    Osteoporosis is a condition where the bones lose mass and density. It is commonly referred to as 'thinning of the bones' and occurs most commonly...

    From: HIV treatments directory

    Information level Level 4

Bone problems features

Bone problems news from aidsmap

More news

Bone problems news selected from other sources

  • Free new tool for health providers to assist physical rehabilitation in people living with HIV

    The free website, entitled "How Rehabilitation Can Help People Living with HIV in Sub-Saharan Africa: An Evidence-Informed Tool for Rehab Providers", was adapted from a Canadian resource and is also downloadable for use on paper. It's designed to be a one-stop resource for physiotherapists, occupational therapists and other health workers who can quickly and easily research the most common HIV-related disabilities, and find evidence-based rehabilitation solutions

    02 December 2015 | Eurekalert Medicine & Health
  • TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

    Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

    12 October 2015 | Monthly Prescribing Reference
  • Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

    A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

    04 September 2015 |
  • ART: Daily Vitamin D and Calcium Stave Off Bone Loss

    Patients with HIV infection who take antiretroviral therapy (ART) can also reduce antiretroviral therapy-related bone loss by 50% by taking daily high-dose vitamin D and calcium supplements, according to a 48-week study.

    17 June 2015 | Medscape
  • The puzzle of thin bones in young MSM

    In Amsterdam, researchers have established a large cohort, called AGEhIV, of both HIV-positive and HIV-negative people of similar age and risk behaviours. Young MSM in this study, regardless of HIV infection, were surprisingly at risk for having thinner-than-normal bones.

    01 October 2014 | CATIE
  • Gilead Sciences: A Preview of Important HIV Drug Study Results

    Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.

    23 September 2014 | The Street
  • CROI 2014: Researchers discuss HIV, aging, and frailty

    People living with HIV are at greater risk of geriatric syndromes such as frailty and difficulty with daily activities than HIV negative people of the same age -- and this can have a significant effect upon their quality of life as they age, according to several studies presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI 2014) last month in Boston.

    08 April 2014 |
  • HIV Drug Linked to Low Bone Density in Babies

    In a cohort study, babies of mothers taking tenofovir (Viread) had an average whole-body bone mineral content about 8 grams less than babies whose mothers did not use the drug, according to George Siberry, MD, of the National Institute of Child Health and Human Development in Bethesda, Md

    07 March 2014 | MedPage Today
  • Primary care key to management of patients with HIV infection

    The HIV Medicine Association of the Infectious Diseases Society of America has updated its HIV care guidelines to reflect the fact that people with HIV are now living normal life spans, and their physicians need to focus on preventive care, including screening for high cholesterol, diabetes and osteoporosis.

    14 November 2013 | Eurekalert Inf Dis
  • TDF/FTC-to-ABC/3TC switch maintains viral suppression, eases bone markers

    A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.

    19 September 2013 | NATAP
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also